Tufts Clinical and Translational Science Institute, Boston, MA
Jessica K Paulus , Furha Iram Cossor , Christina D. Williams , Robert E. Martell , Michael J. Kelley
Background: Although diabetes (DM) is associated with a worse colorectal cancer (CRC) prognosis, metformin (M) use has been associated with improved overall and CRC-specific survival in several prior studies. We examined the impact of M use on overall survival (OS) in patients with type 2 DM and CRC among US veterans while adjusting for treatment, stage and diabetic severity, offering the largest cohort study examining this issue to date. Methods: There were 21,352 patients with CRC were diagnosed between 2001 and 2008 in the US Veterans Health Administration. OS was compared across four groups: patients without DM (n=16,355); patients with DM on M (n= 2,038); patients with DM on anti-DM medications other than M (n=2,136); and patients with DM not on anti-DM medication (n=823). Multivariate Cox proportional hazards models were used to estimate the association between M use, DM and OS while adjusting for age, race, stage, body mass index, HbA1C, comorbidity index, and cancer treatment. Results: Median survival was 61 months in non-diabetics, 67 months in metformin users, 45 months in users of other diabetic medications, and 51 months in diabetics not on anti-DM medication. HbA1C levels were 6.9%, 6.8%, and 6.2% in patients with DM on metformin, other, or no anti-DM medication, respectively. In the subset of CRC patients with DM, those patients taking M had a 21% decrease in the risk of death compared to patients with diabetes taking anti-DM medications other than M (HRadj 0.79; 95% CI 0.73-0.86, p=<0.001), while diabetic patients not on any anti-DM medications had a 13% decrease in risk of death (HRadj 0.87; 95% CI 0.78-0.97, p=0.02). No interaction between M and BMI was observed (p=0.86). In the entire cohort, patients with DM on anti-DM medications other than M had a statistically significant increase in risk of death compared to non-diabetics (HRadj 1.26; 95% CI 1.19-1.33, p=<0.0001). However, patients with DM on M had similar OS as compared to non-diabetics (HRadj 1.05; 95% CI 0.99-1.12, p=0.11), as did patients with DM not on anti-diabetic medication (HRadj1.08; 95% CI 0.99-1.18, p=0.07). Conclusions: Among diabetics with CRC, M use is associated with improved survival as compared to the use of other medications. Metformin may reduce the survival disadvantage associated with DM among CRC patients.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2015 ASCO Annual Meeting
First Author: Amal Al Omari
2024 ASCO Genitourinary Cancers Symposium
First Author: Martin W. Schoen
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Javier Soto Alsar
2019 ASCO Annual Meeting
First Author: Maria Luisa Romero